Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study.
Rossetti B, Gagliardini R, Sterrantino G, Colangeli V, Latini A, Colafigli M, Vignale F, Rusconi S, Di Biagio A, Orofino G, Mezzaroma I, Vullo V, Francisci D, Mastroianni C, Trezzi M, Canovari B, Lamonica S, Ciccullo A, Borghetti A, DʼArminio Monforte A, Di Giambenedetto S, De Luca A; for GUSTA trial study group. Rossetti B, et al. Among authors: trezzi m. J Acquir Immune Defic Syndr. 2019 May 1;81(1):e17-e21. doi: 10.1097/QAI.0000000000001986. J Acquir Immune Defic Syndr. 2019. PMID: 30789452 Free PMC article. Clinical Trial. No abstract available.
Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis).
Rusconi S, Gianotti N, Adorni F, Boeri E, Menzo S, Gonnelli A, Micheli V, Meraviglia P, Trezzi M, Paolini E, Giacometti A, Corsi P, Di Pietro M, Monno L, Punzi G, Zazzi M; ARCA Collaborative Group. Rusconi S, et al. Among authors: trezzi m. J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):373-5. doi: 10.1097/QAI.0b013e3181378f73. J Acquir Immune Defic Syndr. 2007. PMID: 18090302 No abstract available.
Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
Di Giambenedetto S, Zazzi M, Corsi P, Gonnelli A, Di Pietro M, Giacometti A, Almi P, Trezzi M, Boeri E, Gianotti N, Menzo S, Del Gobbo R, Francisci D, Nerli A, Galli L, De Luca A; Antiretroviral Resistance Cohort Analysis Study Group. Di Giambenedetto S, et al. Among authors: trezzi m. Antivir Ther. 2009;14(3):359-69. Antivir Ther. 2009. PMID: 19474470
Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.
Bracciale L, Colafigli M, Zazzi M, Corsi P, Meraviglia P, Micheli V, Maserati R, Gianotti N, Penco G, Setti M, Di Giambenedetto S, Butini L, Vivarelli A, Trezzi M, De Luca A. Bracciale L, et al. Among authors: trezzi m. J Antimicrob Chemother. 2009 Sep;64(3):607-15. doi: 10.1093/jac/dkp246. Epub 2009 Jul 16. J Antimicrob Chemother. 2009. PMID: 19608581
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Zazzi M, et al. J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. J Antimicrob Chemother. 2009. PMID: 19620134 Free article.
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A; UCSC cohort; MASTER cohort; ARCA cohort. Di Giambenedetto S, et al. Among authors: trezzi m. Infection. 2009 Oct;37(5):438-44. doi: 10.1007/s15010-009-8237-x. Epub 2009 Aug 7. Infection. 2009. PMID: 19669091
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group. Prosperi MC, et al. J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927. J Med Virol. 2010. PMID: 20981785
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
Torti C, d'Arminio-Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Luca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts. Torti C, et al. BMC Infect Dis. 2011 Jan 25;11:23. doi: 10.1186/1471-2334-11-23. BMC Infect Dis. 2011. PMID: 21266068 Free PMC article. Clinical Trial.
A novel methodology for large-scale phylogeny partition.
Prosperi MC, Ciccozzi M, Fanti I, Saladini F, Pecorari M, Borghi V, Di Giambenedetto S, Bruzzone B, Capetti A, Vivarelli A, Rusconi S, Re MC, Gismondo MR, Sighinolfi L, Gray RR, Salemi M, Zazzi M, De Luca A; ARCA collaborative group. Prosperi MC, et al. Nat Commun. 2011;2:321. doi: 10.1038/ncomms1325. Epub 2011 May 24. Nat Commun. 2011. PMID: 21610724 Free PMC article.
130 results